Takeda Pharmaceutical Company Limited

Tokyo Medical and Dental University

Ulvac, Inc.

Ulvac Cryogenics Inc.

Institute of Science Tokyo

Kosuke Hidaka

Tomohiro Seki

Yasuo Nakagawa

Masato Yoshikawa

Masaki Seto

Akito Shibuya

Michiyo Mochizuki

Zenyu Shiokawa

Morihisa Saitoh

Yusuke Tominari

Yoshihisa Nakada

Yayoi Nakayama

Taisuke Kato

Tetsuya Nagata

Tsuneo Oda

Takanori Yokota

Shigekazu Sasaki

Hideki Furukawa

Yusuke Sasaki

Paul D Greenspan

Yasufumi Wada

Brian Scott Freeze

Taisuke Tawaraishi

Takatoshi Yogo

Shumpei Murata

Ryosuke Tokunoh

Kenichi Miyata

Atsutoshi Okabe

Masanori Okaniwa

Yukihito Tashiro

Junichi Itoh

Yusuke Adachi

Mitsuki Terashima

Akio Uchida

Hidenori Fukumoto

Naoto Arimura

The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted Calkyl group, a substituted or unsubstituted Calkenyl group, or a substituted or unsubstituted Calkoxy group.

BBB-crossing lipid ligand of hetero nucleic acid

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Nucleic acid complex

Cyclic dinucleotide

There is provided a holding apparatus which is capable of rotatably holding, while cooling to a cryogenic temperature, a to-be-processed object in a vacuum chamber. A holding apparatus for rotatably holding, while cooling, a to-be-processed object in a vacuum chamber Vc, has a stage on which the to-be-processed object is placed, a rotary drive device for rotatably supporting the stage, and a cooling device for cooling the stage. Provided that a stage surface side on which the to-be-processed object is placed is defined as an upside, the rotary drive device has: a tubular rotary shaft body which is mounted on a wall surface of the vacuum chamber, in a penetrating manner, through a first vacuum seal; a connection member for connecting an upper end part of the rotary shaft body and a lower surface of the stage in a manner to define a space below the stage; and a driving motor for driving to rotate the rotary shaft body.

Holding apparatus

Growing community of inventors

Kanagawa, Japan

Kosuke Hidaka